Future Fields Closes Oversubscribed $8M Series A to Turn Flies Into Bioreactors

▤ Summary

Future Fields closed an oversubscribed $8 million Series A round to scale its biomanufacturing platform. The company uses transgenic fruit flies as bioreactors to produce challenging proteins for agriculture, food, and biopharma customers. It will use the new capital to expand commercial capacity, open more production opportunities, and support next-generation medicines and bioproducts. The company also announced a partnership with Protein Evolution to produce AI-engineered proteins. Investors in the round include Amplify Capital, BDC Climate Tech Fund, R7 Partners, and several returning backers.

$ Funding

▦ Linked Companies